Key Insights

Highlights

Treatment Research

1 treatments under study, led by Flotcross Or Crossflot

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06161818Phase 2Recruiting

Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction

Showing all 1 trials

Research Network

Common Treatments

  • Flotcross Or Crossflot1

Active Sponsors

  • Erasmus Medical Center1
  • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)1

Top Investigators

Related Conditions

  • Oesophageal Cancer1
  • Adenocarcinoma Of The Esophagus1
  • Esophageal Cancer1

Activity Timeline